Twelve aqueous extracts prepared from Jordanian plants that are currently used in traditional medicine to treat various types of cancer were tested in mice for their augmentation of natural killer cells in vivo in generating cytotoxicity against YAC tumour targets. After 1 week of oral administration of aqueous extracts of fresh Nigella sativum (N.s.) seeds and Allium sativum (A.s.) bulbs significant augmentation of splenic natural killer (NK) cells (62.3% +/- 6.4% and 52.6% +/-5.4% cytotoxicity, respectively), was obtained in comparison with spontaneous activity (24.5% +/- 1.6%) at 200:1 effector:target ratio. Onopordum acanthium (O.a.) stem and leaves and Allium cepa (A.c.) bulbs showed intermediate augmentation (38.6% +/- 3.8% and 30.6% +/- 3.4% cytotoxicity, respectively) while the rest showed insignificant augmentation activity. The fresh aqueous extract of a mixture of the plants with high and intermediate activity showed little insignificant augmentation activity (72.7% +/- 6.7% cytotoxicity) of NK cells compared with that obtained with each plant alone.

A rapid, simple, and sensitive RP-HPLC analytical method was developed for the simultaneous determination of triclabendazole and ivermectin in combination using a C18 RP column. The mobile phase was acetonitrilemethanolwateracetic acid (56 36 7.5 0.5, v/v/v/v) at a pH of 4.35 and flow rate of 1.0 mL/min. A 245 nm UV detection wavelength was used. Complete validation, including linearity, accuracy, recovery, LOD, LOQ, precision, robustness, stability, and peak purity, was performed. The calibration curve was linear over the range 50.09150.26 g/mL for triclabendazole with r = 0.9999 and 27.0181.02 g/mL for ivermectin with r = 0.9999. Calculated LOD and LOQ for triclabendazole were 0.03 and 0.08 g/mL, respectively, and for ivermectin 0.07 and 0.20 g/mL, respectively. The intraday precision obtained was 98.71 with RSD of 0.87 for triclabendazole and 100.79 with RSD 0.73 for ivermectin. The interday precision obtained was 99.51 with RSD of 0.35 for triclabendazole and 100.55 with RSD of 0.59 for ivermectin. Robustness was also studied, and there was no significant variation of the system suitability of the analytical method with small changes in experimental parameters.

No abstract

No abstract

No abstract